{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:14:39Z","timestamp":1778670879743,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["EY025180"],"award-info":[{"award-number":["EY025180"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["EY025181"],"award-info":[{"award-number":["EY025181"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["EY025182"],"award-info":[{"award-number":["EY025182"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["EY025183"],"award-info":[{"award-number":["EY025183"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["#P30EY002687"],"award-info":[{"award-number":["#P30EY002687"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"NEI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ajo.2018.11.006","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T05:21:27Z","timestamp":1542864087000},"page":"193-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Assessment of the Impact of an Endpoint Committee in the Ocular Hypertension Treatment Study"],"prefix":"10.1016","volume":"199","author":[{"given":"Mae O.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve J.","family":"Higginbotham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale K.","family":"Heuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Richard K.","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan L.","family":"Robin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah A.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley S.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Kass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajo.2018.11.006_bib1","doi-asserted-by":"crossref","first-page":"P112","DOI":"10.1016\/j.ophtha.2015.10.055","article-title":"Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern Guidelines","volume":"123","author":"Prum","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2018.11.006_bib2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1167\/iovs.17-23713","article-title":"Challenges to the common clinical paradigm for diagnosis of glaucomatous damage with OCT and visual fields","volume":"59","author":"Hood","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9975","key":"10.1016\/j.ajo.2018.11.006_bib3","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial","volume":"385","author":"Garway-Heath","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ajo.2018.11.006_bib4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/IJG.0000000000000022","article-title":"Outcome measures in glaucoma: a systematic review of Cochrane Reviews and protocols","volume":"24","author":"Ismail","year":"2015","journal-title":"J Glaucoma"},{"issue":"4","key":"10.1016\/j.ajo.2018.11.006_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0197-2456(94)90046-9","article-title":"The Advanced Glaucoma Intervention Study (Agis) .1. Study design and methods and baseline characteristics of study patients","volume":"15","author":"Brown","year":"1994","journal-title":"Control Clin Trials"},{"issue":"10","key":"10.1016\/j.ajo.2018.11.006_bib6","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2018.11.006_bib7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0161-6420(99)90147-1","article-title":"The Collaborative Initial Glaucoma Treatment Study - study design, methods, and baseline characteristics of enrolled patients","volume":"106","author":"Musch","year":"1999","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2018.11.006_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/archopht.117.5.573","article-title":"The Ocular Hypertension Treatment Study: design and baseline description of the participants","volume":"117","author":"Gordon","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2018.11.006_bib9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ajo.2008.10.007","article-title":"Five-year follow-up optic disc findings of the Collaborative Initial Glaucoma Treatment Study","volume":"147","author":"Parrish","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2018.11.006_bib10","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1167\/iovs.05-1584","article-title":"Optic disc and visual field progression in ocular hypertensive subjects: detection rates, specificity, and agreement","volume":"47","author":"Strouthidis","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl","key":"10.1016\/j.ajo.2018.11.006_bib11","first-page":"335","article-title":"The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975","volume":"24","author":"Leibowitz","year":"1980","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ajo.2018.11.006_bib13","series-title":"Pre-authorisation Evaluation of Medicines for Human Use. Committee for medicinal products for human use (CHMP)","year":"2005"},{"issue":"9","key":"10.1016\/j.ajo.2018.11.006_bib14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archopht.118.9.1187","article-title":"Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group","volume":"118","author":"Keltner","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.006_bib15","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0161-6420(01)00948-4","article-title":"Baseline visual field characteristics in the Ocular Hypertension Treatment Study","volume":"109","author":"Johnson","year":"2002","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2018.11.006_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0002-9394(01)01338-1","article-title":"The Ocular Hypertension Treatment Study: reproducibility of cup\/disk ratio measurements over time at an optic disc reading center","volume":"133","author":"Feuer","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2018.11.006_bib17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2018.11.006_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2106\/JBJS.L.00190","article-title":"Adjudicating outcomes: fundamentals","volume":"94","author":"Vannabouathong","year":"2012","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"10.1016\/j.ajo.2018.11.006_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13063-017-1995-3","article-title":"A comparison of approaches for adjudicating outcomes in clinical trials","volume":"18","author":"Kahan","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.ajo.2018.11.006_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ahj.2017.05.009","article-title":"Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: rationale and best practices. A report from the cardiac safety research consortium","volume":"190","author":"Seltzer","year":"2017","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.ajo.2018.11.006_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1740774515611889","article-title":"Architecture design of a generic centralized adjudication module integrated in a web-based clinical trial management system","volume":"13","author":"Zhao","year":"2016","journal-title":"Clin Trials"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.006_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1740774509105223","article-title":"Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs","volume":"6","author":"Pogue","year":"2009","journal-title":"Clin Trials"},{"issue":"6","key":"10.1016\/j.ajo.2018.11.006_bib23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bjo.87.6.726","article-title":"Interobserver agreement on visual field progression in glaucoma: a comparison of methods","volume":"87","author":"Viswanathan","year":"2003","journal-title":"Br J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939418306457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939418306457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:39:03Z","timestamp":1757597943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939418306457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":22,"alternative-id":["S0002939418306457"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2018.11.006","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of the Impact of an Endpoint Committee in the Ocular Hypertension Treatment Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2018.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}